Mycotopia Therapies Stock Price, News & Analysis

TPIA was the ticker symbol for Mycotopia Therapies Inc., a company that has transitioned its business focus and corporate identity over time. According to company announcements, Mycotopia Therapies evolved from a biopharmaceutical enterprise centered on medical psychedelics and mental wellness into an artificial intelligence and robotics platform operating as AIBiotics. The company has disclosed that it develops and manages companies and technologies that integrate artificial intelligence (AI) and robotics, and that it has pursued a name and symbol change to reflect this shift. A later corporate action announced that the company’s name would change to AIBiotics, Inc. and its trading symbol to AIBT, with TPIA representing the historical symbol.

In its earlier phase, Mycotopia Therapies described itself as a biopharma company focused on research, technology, and the development of medical psychedelics. The company stated that it concentrated on mental wellness through psychedelic-enhanced psychotherapy, working with mental wellness practitioners and technology to support patients dealing with conditions such as anxiety, depression and other mental health challenges. Mycotopia also reported activities related to naturally derived psilocybin, functional mushrooms and plant-based therapeutic concepts, including work in jurisdictions where psilocybin is legal and partnerships aimed at supplying naturally derived compounds to researchers and institutions.

Over time, Mycotopia Therapies announced a strategic transition toward AI and robotics. The company reported acquiring certain AI robotics assets from Philon Labs, including patents related to home health products branded as Phill Robot and Milkyway. These products are described in company communications as AI-powered devices intended to address real-world wellness and caregiving needs. Phill Robot is presented as an AI-controlled massage, scratch and caress robot with a long-range arm, significant massage force and a variety of massage patterns, designed to deliver personalized, spa-like experiences in the home. Milkyway is described as a smart refrigerator for breast milk storage bags, using an automated vertical rotating storage system to organize bags by date and volume and to support even freezing.

Following this acquisition, Mycotopia Therapies stated that it would change its name to AiBotics (later referenced as AIBiotics) to align with a focus on AI-enhanced products. Subsequent communications under the AIBiotics name describe the company as a developer and manager of AI- and robotics-enhanced companies and technologies. AIBiotics reports that it focuses on identifying, developing and scaling businesses that benefit from automation, machine learning and advanced robotics across multiple industries, with specific references to healthcare, wellness, manufacturing, logistics and music technology.

Under the AIBiotics identity, the company has highlighted Phill Robot and Milkyway as flagship products. Company materials describe Phill Robot as an AI-powered massage robot with a patented foldable arm system, a defined reach and massage force, and integration with Internet of Things (IoT) devices and apps for customization and control. The robot is portrayed as capable of delivering personalized massage experiences, with development efforts focused on motion precision, pose detection, autonomous calibration and acupressure-based software. Milkyway is described as a smart refrigerator designed specifically for breast milk storage, featuring a vertical rotating system to organize bags by date and ounces and app integration for monitoring temperature and inventory.

The company has also reported plans and agreements related to the broader AI and technology ecosystem. Communications under the AIBiotics and Mycotopia brands reference a letter of intent to acquire DigiTrax Entertainment Inc., a music technology company that uses AI-based algorithms trained in music theory. According to these disclosures, DigiTrax holds multiple U.S. patents in music AI and a music catalog, and operates AI-driven music tools and platforms. The proposed transaction is described as intended to expand AIBiotics’ AI portfolio and market presence, with DigiTrax expected to become a subsidiary of AIBiotics if definitive agreements are completed.

Historically, Mycotopia Therapies also announced a series of strategic initiatives in the psychedelic and functional mushroom sectors. The company reported a planned combination with Ei.Ventures under a new entity, PSLY.COM, focused on botanical psychedelic active pharmaceutical ingredients (APIs) and plant-based therapeutics. It also disclosed supply and distribution agreements with HAVN Life Sciences for naturally derived psilocybin compounds, functional mushrooms and natural health products, as well as collaborations aimed at developing mushroom-based nutraceuticals and mental wellness platforms. Some of these plans, including a previously announced merger with Ei.Ventures and PSLY.com, were later reported as terminated or modified.

In Europe, Mycotopia Therapies announced a partnership with PsychedelicsEUROPE to explore opportunities within the regulatory framework for medicinal use of psychedelics for mental health in the EU market. This collaboration was described as focusing on psychedelic research and new models of care within evolving European regulations. These activities reflect the company’s earlier emphasis on psychedelic therapies and mental health before its transition to AI and robotics.

As part of its corporate evolution, the company has communicated that TPIA shares are associated with Mycotopia Therapies dba AIBiotics and that a name and ticker change to AIBiotics, Inc. and AIBT was approved under FINRA Rule 6490, with a specified market effective date. This positions TPIA primarily as a historical symbol linked to the company’s earlier psychedelic-focused operations and its subsequent transformation into an AI and robotics-oriented enterprise under the AIBiotics name.

Business evolution and focus areas

Based on company disclosures, the business associated with the TPIA symbol has covered several focus areas over time:

• Medical psychedelics and mental wellness: Research, technology and development of medical psychedelics; psychedelic-enhanced psychotherapy; collaborations around botanical psilocybin and functional mushroom products; and partnerships aimed at advancing psychedelic medicine and mental health solutions.
• AI and robotics for wellness and caregiving: Acquisition and development of Phill Robot and Milkyway, which are described as AI robotics-based home health and caregiving products addressing relaxation, self-care and breast milk storage.
• AI-driven technology portfolio: Under the AIBiotics identity, a stated focus on developing and managing companies and technologies that use AI and robotics across multiple industries, including wellness, healthcare and music technology, with a reported letter of intent to acquire DigiTrax Entertainment.

Historical context for investors and researchers

For users researching TPIA stock, it is important to recognize that the symbol is tied to a company that has undergone significant strategic and branding changes. Earlier communications emphasize psychedelic therapies, mental wellness and mushroom-based products, while later disclosures highlight AI and robotics, home health devices and AI-driven music technology. Corporate announcements also describe planned and terminated merger transactions, strategic partnerships and a formal process to change the company’s name and trading symbol.

Because of these transitions, TPIA is best understood as the historical identifier for Mycotopia Therapies and its subsequent operations doing business as AIBiotics. For current information on the company’s activities, investors typically refer to the most recent corporate communications and the updated name and symbol referenced in regulatory and market announcements.